Citigroup downgraded Moderna from Hold to Sell, citing that the stock's recent surge is not supported by its current cancer vaccine pipeline. Despite a 590% rise in 2026, Citi's analyst raised the price target to $80, still well below Moderna's trading price around $203.46. The downgrade focuses on uncertainties about the broad effectiveness of Moderna's personalized cancer vaccine, developed with Merck, with more data expected in October. Meanwhile, Merck and Pfizer stocks showed little change, highlighting Moderna's unique volatility amid the biotech rally.
Moderna shares are down 6.17% on Pluang, trading at USD 190.91 as of Sep 30, 2026 20:51 WIB, reflecting notable volatility compared to Merck and Pfizer, which are relatively stable with 1-day changes of -0.82% and -0.33% respectively. Merck trades at USD 148.09 and Pfizer at USD 28.63, with strong buy interest on the platform.
